

**VOTING QUESTION #2 TO THE COMMITTEE**

**FOR REBIOTIX**

**September 22, 2022**

**Are the available data adequate to support the safety of REBYOTA when administered to adults 18 years of age and older following antibiotic treatment for recurrent CDI?**

**Please vote Yes or No**